Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2018-02-08 Regulatory Filings
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Penthrox approved in Latvia 3 pages 484.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 9 February 2018 about the approval of the product Penthrox for sale in Latvia. It discusses marketing authorization and regulatory progress in European countries. The content is a brief corporate announcement about product approval and regulatory status, without any financial data, management changes, voting results, or detailed reports. The document length is 3866 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of financial results, audit information, or other report types. Therefore, this document fits best as a Regulatory Filing (RNS), which is a general regulatory announcement category for filings that do not fit other specific categories.
2018-02-08 English
Change of Director's Interest Notice 2 pages 250.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, nature of the interest, and dates. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It is not an annual report, earnings release, or any other financial report but specifically a director's dealing notice. Therefore, the correct classification is 'DIRS' (Director's Dealing). The document length is 3852 characters, consistent with a detailed insider trading notice rather than a full financial report.
2018-02-04 English
Penthrox approved in Slovakia 3 pages 487.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 1 February 2018 about the approval of the drug Penthrox in Slovakia by the SUKL (State Institute for Drug Control). It discusses marketing authorization and regulatory progress in European countries. The content is a corporate announcement about product approval and regulatory status, not a financial report, earnings release, or management discussion. The document length is 3838 characters, which is relatively short and consistent with an announcement rather than a detailed report. There is no financial data, no mention of shareholder votes, no management changes, no legal proceedings, no capital changes, and no conference call transcript. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about product approval and marketing authorization, which does not fit into any more specific category.
2018-01-31 English
Penthrox approved in Austria 3 pages 483.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 29 January 2018 about the approval of the product Penthrox in Austria. It discusses marketing authorization and regulatory progress in Europe. The content is a corporate announcement about product approval and regulatory status, not a financial report, earnings release, or management discussion. The document length is 3859 characters, which is relatively short and typical for an announcement. There is no indication of financial data, voting results, management changes, or other report types. This fits best with a Regulatory Filings (RNS) category, which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2018-01-28 English
Penthrox approved in Denmark 2 pages 260.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 24 January 2018 about the approval of the product Penthrox for sale in Denmark by the Danish Medicines Agency. It contains no financial data, no discussion of financial results, no management or board changes, no voting results, no legal proceedings, no capital or financing updates, and no detailed report content. The document is a brief announcement of a regulatory approval event related to the company's product. It is short (3437 characters) and does not contain any report or financial statements. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2018-01-23 English
Penthrox approved in Iceland 2 pages 245.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 22 January 2018 about the approval of the drug Penthrox for sale in Iceland. It contains no financial data, no regulatory filings, no management or board changes, no voting results, no earnings or annual report information. It is a straightforward announcement of a marketing authorization approval, which is a regulatory update about the company's product status. The document length is 3810 characters, which is relatively short and does not contain detailed financial or operational reports. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2018-01-21 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.